title: Protection by taurine against INOS-dependent DNA damage in heavily exercised skeletal muscle by inhibition of the NF-κB signaling pathway.
abstract: Taurine protects against tissue damage in a variety of models involving inflammation, especially the muscle. We set up a heavy exercise bout protocol for rats consisting of climbing ran on a treadmill to examine the effect of an intraabdominal dose of taurine (300 mg/kg/day) administered 1 h before heavy exercise for ten consecutive days. Each group ran on the treadmill at 20 m/min, 25% grade, for 20 min or until exhaustion within 20 min once each 10 days. Exhaustion was the point when an animal was unable to right itself when placed on its side. The muscle damage was associated with an increased accumulation of 8-nitroguanine and 8-OHdG in the nuclei of skeletal muscle cells. The immunoreactivities for NF-κB and iNOS were also increased in the exercise group. Taurine ameliorated heavy exercise-induced muscle DNA damage to a significant extent since it reduced the accumulation of 8-nitroguanine and 8-OHdG, possibly by down-regulating the expression of iNOS through a modulatory action on NF-κB signaling pathway. This study demonstrates for the first time that taurine can protect against intense exercise-induced nitrosative inflammation and ensuing DNA damage in the skeletal muscle of rats by preventing iNOS expression and the nitrosative stress generated by heavy exercise.
authors: Faculty of Health Science and Pharmaceutical Sciences, Suzuka University of Medical Science, Mie, Japan.
authors: Hiromichi
authors: H
authors: Sugiura
authors: Shinya
authors: S
authors: Okita
authors: Toshihiro
authors: T
authors: Kato
authors: Toru
authors: T
authors: Naka
authors: Shosuke
authors: S
authors: Kawanishi
authors: Shiho
authors: S
authors: Ohnishi
authors: Yoshiharu
authors: Y
authors: Oshida
authors: Ning
authors: N
authors: Ma
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D002452:Cell Count; D048429:Cell Size; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D006147:Guanine / Q000031:analogs & derivatives / Q000378:metabolism; D008297:Male; D032342:Muscle Cells / Q000187:drug effects / Q000473:pathology; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D010805:Physical Conditioning, Animal; D020011:Protective Agents / Q000494:pharmacology*; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects; D013654:Taurine / Q000494:pharmacology*
chemical_list: C095838:8-nitroguanine; D016328:NF-kappa B; D020011:Protective Agents; D013654:Taurine; D006147:Guanine; D000080242:8-Hydroxy-2'-Deoxyguanosine; D052247:Nitric Oxide Synthase Type II; D003849:Deoxyguanosine